Lansoprazolo Ratiopharm

Lansoprazole, the active ingredient in Lansoprazolo Ratiopharm, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease, and in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Lansoprazolo Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Lansoprazole is a proton pump inhibitor indicated for several acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and reflux symptoms by reducing stomach acidity. - Erosive esophagitis: promotes healing of inflamed esophageal tissue caused by acid exposure. - Peptic ulcer disease: supports ulcer healing and prevents recurrence through sustained acid suppression. - Helicobacter pylori eradication (in combination therapy): enhances antibiotic effectiveness by creating a less acidic gastric environment.

Lansoprazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may be self‑limiting. - Nausea: feeling of queasiness, sometimes accompanied by vomiting. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical care. - Clostridium difficile infection: severe colitis presenting with watery diarrhea. - Hypomagnesemia: low magnesium levels causing muscle cramps or cardiac arrhythmia. - Liver enzyme elevations: signs of hepatic stress detectable in blood tests. - Pancreatitis: inflammation of the pancreas with abdominal pain and nausea. - Interstitial nephritis: kidney inflammation presenting with reduced urine output or swelling.

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor magnesium levels: prolonged treatment may lead to hypomagnesemia. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution with concomitant warfarin: potential for increased bleeding risk. - Discuss pregnancy risk: evaluate benefits versus potential fetal exposure. - Store at room temperature: keep in the original container, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption leading to sub‑therapeutic HIV control. - Methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible elevation of INR and bleeding tendency. - Phenytoin: reduced plasma concentrations, potentially lowering seizure control. - Digoxin: increased serum levels, raising the risk of cardiac toxicity.